Hyphens Pharma Licenses Innovative Cerapro® MED Cream Across Europe

Hyphens Pharma Licenses Cerapro® MED Cream in Europe

Hyphens Pharma International Limited, a leading specialty pharmaceutical and consumer healthcare company from Singapore, has recently made headlines with its decision to license the innovative Cerapro® MED Skin Barrier Cream to Louis Widmer SA. This groundbreaking agreement allows Louis Widmer to commercialize the cream across six European nations: Switzerland, Liechtenstein, Austria, Belgium, Luxembourg, and the Netherlands.

Overview of Cerapro® MED

Cerapro® is a patented cream known for lowering skin pH levels. Approved as a medical device under the stringent European Medical Device Regulation and bearing the CE Mark, it offers a promising treatment option for individuals dealing with atopic dermatitis—a common form of eczema that affects millions globally. The product's unique formulation not only helps restore the skin barrier but also addresses elevated skin pH levels, which are fundamental contributors to skin conditions like eczema. Additionally, by lowering the skin's pH, Cerapro® supports the skin's innate antimicrobial defense mechanisms.

This new partnership represents a significant opportunity for both Hyphens Pharma and Louis Widmer as they combine their expertise to improve patient care. Hyphens Pharma, with its established reputation, will benefit from Louis Widmer's comprehensive experience in dermatology, enabling swift access to dermatologists and pediatricians in the specified markets.

A Win-Win Collaboration

Hyphens Pharma will receive both an upfront fee and royalties from the sales generated by Cerapro® in the European markets, ensuring sustainable revenue while expanding its reach. Mr. Lim See Wah, Chairman and CEO of Hyphens Pharma, expressed enthusiasm for this collaboration, stating, "This milestone partnership with Louis Widmer underlines our commitment to innovation and patient care. With Louis Widmer’s strong presence in the dermatology field, we aim to deliver Cerapro® effectively to patients across Europe and continue exploring new growth avenues."

Louis Widmer, a well-respected name in the cosmetics and pharmaceuticals industry since 1960, is committed to offering high-quality dermatological products. Their CEO, Ms. Annemarie Widmer, echoed the sentiment, stating, "We are excited to partner with Hyphens Pharma to introduce Cerapro® to our markets, which will serve as a clinically proven solution for atopic dermatitis within our established Remederm line. Our commitment to providing effective skincare solutions is now bolstered with Cerapro’s launch, further enhancing our portfolio in this critical care sector."

Looking Ahead: 2026 Launch Plans

The launch of Cerapro® in these six European countries is targeted for 2026, with preparations already underway. This timeline allows both companies to ensure the product meets all necessary regulatory standards and positions the marketing strategies effectively to introduce Cerapro® to healthcare professionals and patients alike.

As the healthcare industry continues evolving, partnerships like this one between Hyphens Pharma and Louis Widmer represent strategic moves to improve patient outcomes through innovative solutions. With Cerapro®, patients can look forward to new hope in managing their skin conditions, marking a significant step toward improved quality of life. The collaboration also reflects a shared vision between both companies to elevate healthcare offerings and ensures that patients have access to scientifically backed solutions for their dermatological needs.

Conclusion

The licensing of Cerapro® MED Skin Barrier Cream symbolizes an exciting development in the realm of skincare, particularly for those suffering from atopic dermatitis. By combining the strengths and expertise of Hyphens Pharma and Louis Widmer, the two companies are poised to make a meaningful impact in the European healthcare market in the years to come. As anticipation builds around the 2026 launch, both companies are thoroughly committed to providing high-quality, effective solutions that prioritize patient health and well-being.